Conditions: Hepatic Encephalopathy
Allocation: RANDOMIZED | Intervention model: PARALLEL
Enrollment: 299
Healthy volunteers: no

Brief summary:
The purpose of this study is to determine if the study drug is safe and effective in preventing hepatic encephalopathy (HE).

Detailed description:

Arms:
arm 1: Participants were administered a single rifaximin 550 milligram (mg) tablet 2 times per day (approximately every 12 hours) for 6 months or until a breakthrough episode of hepatic encephalopathy or another reason for discontinuation. arm 2: Participants were administered a single matching placebo tablet 2 times per day (approximately every 12 hours) for 6 months or until a breakthrough episode of hepatic encephalopathy or another reason for discontinuation.

Interventions: intervention 1: Rifaximin intervention 2: Placebo
Intervention descriptions: intervention 1: Oral intervention 2: Oral

Protocol document: